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In April 2016, the International Agency for Re-
search on Cancer (IARC), based in Lyon, France, 
convened a working group to reassess the pre-
ventive effects of weight control on cancer risk. 
(The members of the working group for volume 
16 of the IARC Handbooks are listed at the end 
of the article; affiliations are provided in the 
Supplementary Appendix, available with the full 
text of this article at NEJM.org.) Overweight and 
obesity are the abnormal or excessive accumula-
tion of body fat that present a risk to health. The 
body-mass index (BMI, the weight in kilograms 
divided by the square of the height in meters) is 
a good proxy for assessing overall body fatness. 
Among adults, overweight is defined as a BMI of 
25.0 to 29.9 and obesity as a BMI of 30 or more.1 
Obesity can further be divided into class 1 (BMI, 
30.0 to 34.9), class 2 (BMI, 35.0 to 39.9), and 
class 3 (BMI, ≥40.0) (Table 1).
Worldwide, an estimated 640 million adults 
in 2014 (an increase by a factor of 6 since 1975) 
and 110 million children and adolescents in 2013 
(an increase by a factor of 2 since 1980) were 
obese. The estimated age-standardized prevalence 
of obesity in 2014 was 10.8% among men, 14.9% 
among women,2 and 5.0% among children,3 and 
globally more people are overweight or obese than 
are underweight.
In 2013, an estimated 4.5 million deaths 
worldwide were caused by overweight and obesity; 
on the basis of recent estimates, the obesity-related 
cancer burden represents up to 9% of the cancer 
burden among women in North America, Europe, 
and the Middle East.4 Body fatness and weight 
gain throughout the life course are largely deter-
mined by modifiable risk factors, such as excess 
energy intake (food and drink) and (to a lesser 
extent) physical inactivity, which are the main 
drivers of the obesity epidemic. In 2002, the previ-
ous IARC working group concluded that there 
was sufficient evidence for a cancer-preventive 
effect of avoidance of weight gain for cancers of 
the colon, esophagus (adenocarcinoma), kidney 
(renal-cell), breast (postmenopausal), and corpus 
uteri.5
Epidemiologic Studies
For the current reassessment, most of the more 
than 1000 epidemiologic studies that we re-
viewed were observational studies on cancer risk 
and excess body fatness, because studies, includ-
ing clinical trials, of weight-loss or weight-con-
trol interventions were sparse. Consequently, the 
evaluations were based on increased risks asso-
ciated with excess body fatness rather than re-
duced risks associated with preventive interven-
tions. Most studies provided risk estimates for 
adult BMI, whereas some provided estimates for 
BMI or body shape in childhood or adolescence, 
changes in BMI or weight over time, or other 
indicators of adiposity, such as waist circumfer-
ence. When adequate meta-analyses of observa-
tional studies were available, we also took rela-
tive-risk estimates into account. Most relative 
risks are provided relative to a BMI of 18.5 to 24.9.
On the basis of these data, we termed the at-
tribute “excess body fatness” and reaffirmed that 
Class Body-Mass Index
Overweight 25.0–29.9
Obesity
Class 1 30.0–34.9
Class 2 35.0–39.9
Class 3 ≥40.0
Table 1. Definitions of Classes of Overweight and Obesity.
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the absence of excess body fatness lowers the 
risk of cancer at the organ sites that have been 
identified previously (Table 2). Furthermore, we 
identified an additional eight cancers for which 
there is now also sufficient evidence that the 
absence of body fatness lowers cancer risk, includ-
ing cancers of the gastric cardia, liver, gallbladder, 
pancreas, ovary, and thyroid, as well as multiple 
myeloma and meningioma. (For detailed infor-
mation on the evaluation criteria, see the working 
procedures section of the IARC Handbooks of 
Cancer Prevention website at http://handbooks 
 . iarc . fr/ workingprocedures/ index1 . php.)
For cancers of the colon, rectum, gastric cardia, 
liver, gallbladder, pancreas, and kidney and for 
esophageal adenocarcinoma, significant associ-
ations between BMI and cancer risk were report-
ed, with positive dose–response relationships. 
Relative risks from meta-analyses or pooled anal-
yses were 1.2 to 1.5 for overweight and 1.5 to 1.8 
for obesity with respect to cancers of the colon,6,7 
gastric cardia,8 liver,9 gallbladder,10 pancreas,11 
and kidney12; the relative risk for esophageal ad-
enocarcinoma was up to 4.8 for a BMI of 40 or 
more.13 Results that were based on waist circum-
ference were generally consistent with those re-
ported for BMI. When studies from different 
geographic regions were available (for cancers of 
the colon, gastric cardia, and liver, as well as 
esophageal adenocarcinoma), the results were con-
sistent across regions.14 Stratification according to 
sex, when available, generally showed similarly 
increased risks among men and women. Studies 
of mendelian randomization (which involve as-
signing people to groups on the basis of geno-
typic variation that may be associated with a 
particular risk factor) allow leveraging the prop-
erties of genetic variation to overcome potential 
limitations present in observational epidemio-
logic studies. Results from such studies on can-
cer of the colorectum15 and esophageal adeno-
carcinoma16 were in agreement with those from 
cohort and case–control studies.
Positive associations have been observed be-
tween adult BMI and postmenopausal breast 
cancer in numerous studies (relative risk, ap-
proximately 1.1 per 5 BMI units),6 particularly 
for estrogen-receptor–positive tumors. Waist cir-
cumference and body-weight gain in adulthood 
were also positively associated with the risk of 
postmenopausal breast cancer. For premenopaus-
al breast cancer, consistent inverse associations 
have been observed between BMI and risk.6 How-
ever, data on associations with waist circumfer-
ence or body-weight gain were inconsistent. These 
differences remain not fully explained.
The association between BMI and endometri al 
cancer was particularly pronounced for type 1 
endometrial cancer. There was a strong dose–
response relationship, with relative risks of ap-
proximately 1.5 for overweight, 2.5 for class 1 
obesity, 4.5 for class 2 obesity, and 7.1 for class 
3 obesity.17 A modest positive association was 
observed for epithelial ovarian cancer, with a rela-
tive risk of 1.1.18 Results from studies that used 
mendelian randomization were consistent with 
these findings.19 Among women who had received 
hormone-replacement therapy, the strength of the 
association with excess body fatness was reduced 
for endometrial cancer,20 and no association was 
observed for ovarian cancer18 or postmenopausal 
breast cancer.21
For multiple myeloma, the available data 
showed positive associations with adult BMI, with 
relative risks of approximately 1.2 for overweight, 
1.2 for class 1 obesity, and 1.5 for class 2 or 3 
obesity.22 On the basis of several cohort or 
case–control studies, a positive association was 
observed between BMI and the risk of meningi-
oma23 and thyroid cancer.24 In addition to the 
cancer sites for which there was sufficient evi-
dence, we concluded that there is limited evidence 
for an association between excess body fatness 
and fatal prostate cancer,25 diffuse large B-cell 
lymphoma,26 and male breast cancer.27
We reviewed studies of eight other cancers for 
which the evidence for an association was consid-
ered inadequate, owing to limited data, inconsis-
tent results, or no data suggesting an association: 
cancers of the lung, esophagus (squamous-cell 
carcinoma), gastric noncardia, extrahepatic bili-
ary tract, skin (cutaneous melanoma), testis, uri-
nary bladder, and brain or spinal cord (glioma).
In addition, we reviewed data pertaining to 
BMI in childhood, adolescence, and young adult-
hood (≤25 years of age) to assess whether in-
creased BMI at these ages is linked with cancer 
in adult life. Positive associations were reported 
for several cancers also known to be associated 
with increased adult BMI, with the notable ex-
ception of postmenopausal breast cancer. The 
associations were generally similar to those with 
adult BMI, despite some differences in magni-
tude and patterns.
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We assessed reviews of the association between 
body fatness on cancer recurrence and survival 
after diagnosis and noted considerable variation 
in study design, setting, and timing of body-fat-
ness measurement relative to cancer diagnosis. 
There was a large volume of evidence supporting 
an association between increased BMI near the 
time of cancer diagnosis and reduced survival in 
patients with breast cancer, whereas evidence for 
other cancers was sparse and less consistent. One 
Cancer Site or Type
Strength of the Evidence 
in Humans†
Relative Risk of the Highest  
BMI Category Evaluated  
versus Normal BMI (95% CI)‡
Esophagus: adenocarcinoma Sufficient 4.8 (3.0–7.7)
Gastric cardia Sufficient 1.8 (1.3–2.5)
Colon and rectum Sufficient 1.3 (1.3–1.4)
Liver Sufficient 1.8 (1.6–2.1)
Gallbladder Sufficient 1.3 (1.2–1.4)
Pancreas Sufficient 1.5 (1.2–1.8)
Breast: postmenopausal Sufficient 1.1 (1.1–1.2)§
Corpus uteri Sufficient 7.1 (6.3–8.1)
Ovary Sufficient 1.1 (1.1–1.2)
Kidney: renal‑cell Sufficient 1.8 (1.7–1.9)
Meningioma Sufficient 1.5 (1.3–1.8)
Thyroid Sufficient 1.1 (1.0–1.1)§
Multiple myeloma Sufficient 1.5 (1.2–2.0)
Male breast cancer Limited NA
Fatal prostate cancer Limited NA
Diffuse large B‑cell lymphoma Limited NA
Esophagus: squamous‑cell carcinoma Inadequate NA
Gastric noncardia Inadequate NA
Extrahepatic biliary tract Inadequate NA
Lung Inadequate NA
Skin: cutaneous melanoma Inadequate NA
Testis Inadequate NA
Urinary bladder Inadequate NA
Brain or spinal cord: glioma Inadequate NA
*  BMI denotes body‑mass index, CI confidence interval, and NA not applicable.
†  Sufficient evidence indicates that the International Agency for Research on Cancer Handbook Working Group considers 
that a preventive relationship has been established between the intervention (in this case, the absence of excess body 
fatness) and the risk of cancer in humans — that is, a preventive association has been observed in studies in which 
chance, bias, and confounding could be ruled out with confidence. Limited evidence indicates that a reduced risk of 
cancer is associated with the intervention for which a preventive effect is considered credible by the working group, but 
chance, bias, or confounding could not be ruled out with confidence. Inadequate evidence indicates that the available 
studies are not of sufficient quality, consistency, or statistical power to permit a conclusion regarding the presence or 
absence of a cancer‑preventive effect of the intervention or that no data on the prevention of cancer by this intervention 
in humans are available. Additional information on the criteria for classification of the evidence is available at http://
handbooks . iarc . fr/ docs/ Handbook16_Working‑Procedures . PrimaryPrevention . pdf.
‡  For cancer sites with sufficient evidence, the relative risk reported in the most recent or comprehensive meta‑analysis 
or pooled analysis is presented. The evaluation in the previous column is based on the entire body of data available at 
the time of the meeting (April 5–12, 2016) and reviewed by the working group and not solely on the relative risk pre‑
sented in this column. Normal BMI is defined as 18.5 to 24.9.
§  Shown is the relative risk per 5 BMI units.
Table 2. Strength of the Evidence for a Cancer-Preventive Effect of the Absence of Excess Body Fatness, According to 
Cancer Site or Type.*
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intervention trial, in which a low-fat diet interven-
tion led to modest weight loss, resulted in a re-
duction in breast-cancer recurrence.28
Data on body-weight loss, either from obser-
vational studies21 or from follow-up of patients 
undergoing bariatric surgery,29 suggested that in-
tentional weight loss may reduce cancer risk, 
notably for breast and endometrial cancer. How-
ever, the number and quality of these studies were 
judged to be insufficient for a formal evaluation.
Studies in Experimental Animal s
Numerous models in experimental animals have 
been used to study the association between obe-
sity and cancer at various organ sites. Overall, 
the data showed that obesity in rodents promotes 
tumorigenesis and increases the age-specific inci-
dence of cancers of the mammary gland, colon, 
liver, pancreas, prostate (advanced stage), and 
skin, as well as, to a lesser extent, leukemia.30,31
Similarly, a large number of studies in several 
rodent models evaluated associations between 
caloric or dietary restriction, which limits body-
weight gain in comparison with controls fed ad 
libitum, and the prevention of tumor development 
or progression. We concluded that there is suffi-
cient evidence in experimental animals for a can-
cer-preventive effect of limitation of body-weight 
gain by caloric or dietary restriction for cancers 
of the mammary gland, colon, liver, pancreas, 
skin, and pituitary gland. In addition, an inverse 
association was observed between caloric or di-
etary restriction and cancer of the prostate, lym-
phoma, and leukemia.
Mechanistic Data
We identified which cellular and molecular mech-
anisms that are known to be altered during car-
cinogenesis32,33 could be causally linked with 
obesity, and we evaluated the relevance of each 
mechanism for cancer overall and for specific 
organ sites when sufficient data were available. 
Obesity is associated with substantial metabolic 
and endocrine abnormalities, including altera-
tions in sex hormone metabolism, insulin and 
insulin-like growth factor (IGF) signaling, and 
adipokines or inflammatory pathways.34,35 Evi-
dence for a role of sex hormone metabolism and 
of chronic inflammation in mediating the obe-
sity–cancer relation is strong, and evidence for a 
role of insulin and IGF signaling is moderate. In 
addition, there was convincing evidence that in-
tentional body-weight loss positively affects these 
mechanisms. The beneficial effects on cancer risk 
appear to be mediated, at least in part, by regula-
tion of the balance between cell proliferation and 
apoptosis,36 known determinants in carcinogenesis.
Evaluation and Conclusions
On the basis of the available data, we concluded 
that the absence of excess body fatness lowers the 
risk of most cancers. In addition, a review of stud-
ies in experimental animals and mechanistic data 
suggest a causal cancer-preventive effect of in-
tentional weight loss, although evidence in hu-
mans remains to be established.
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